X

Trial Profile

Risk of relapse in adult patients with multiple sclerosis treated with dimethyl fumarate versus fingolimod and teriflunomide

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimethyl fumarate (Primary) ; Fingolimod; Teriflunomide
Indications Multiple sclerosis
Focus Therapeutic Use

Most Recent Events

27 Apr 2018 Results assessing effect of dimethyl fumarate versus fingolimod and teriflunomide in adult patients with multipe sclerosis, were presented at the 70th Annual Meeting of the American Academy of Neurology.
03 May 2017 New trial record
28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com